Company intelligence / Profile preview

Aeonian Pharmaceuticals

Berkeley (San Francisco Bay Area), California, United States

Ownership: Private
Development stage: Other

Overview

Aeovian's lead candidate AV078, a first-in-class CNS-penetrant selective mTORC1 inhibitor, has completed Phase 1 dosing in healthy volunteers and advanced to Phase 2 studies in adult and pediatric patients with TSC refractory epilepsy[2][3]. The company is conducting preclinical work in age-related and chronic conditions characterized by inflammation and metabolic dysfunction[6].

Therapeutic areas: NeurologyOtherMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Evotec (drug discovery and development partnership since 2017)Hevolution Foundation (Series B lead investor)

Beyond the preview

Go deeper on Aeonian Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeonian Pharmaceuticals.

Explore the full profile